Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:4/14/2009

VIENNA, Va., April 14 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI Corporation (NYSE AMEX: CVM) to its shareholders:

Dear Fellow Shareholders:

A very important event has just transpired for our company. Dendreon Corporation has announced that its pivotal Phase III trial with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control. The full data from the 512 patient study will be presented on April 28 at the American Urological Association conference.

The significance of Dendreon's success to CEL-SCI is great. For years most investors have shunned the cancer immunotherapy space because of the many failures of various companies involved in the space. While we at CEL-SCI have always tried to differentiate why our immunotherapy approach to treating cancer should be successful where other immunotherapy approaches have failed, the whole cancer immunotherapy space has been so tainted that it was almost impossible to be heard. The successful outcome of the Dendreon study gives the cancer immunotherapy field the needed validation to attract new money to the space. The success of Dendreon proves that it is possible to harness the human immune system against a patient's own cancer.

Geert Kersten, CEO of CEL-SCI said, "We believe that the success of Dendreon validates the cancer immunotherapy area as a promising alternative/adjunct to existing cancer therapies and think that it could lead to enhanced opportunities for CEL-SCI in both the investment and scientific communities."

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half ye
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Calif. , July 22, 2014  Based ... imaging (MRI) market, Frost & Sullivan recognizes Siemens ... Product Leadership. Siemens Healthcare,s FREEZEit solution, which employs ... need for robust and motion-insensitive imaging. The solution,s ... the evolution of body MRI imaging in the ...
(Date:7/22/2014)... , July 22, 2014 Sanofi Pasteur, the ... SNY ), announced today that the first lots of Fluzone ... season have been released by the U.S. Food and Drug ... 21, 2014, representing the first of at least 65 million ... will be delivered to U.S. health care providers and pharmacies ...
(Date:7/22/2014)... , July 22, 2014 Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, announced today that the U.S. Food ... New Drug, or IND, application.  Such clearance will permit ... aramchol, in the United States ...
Breaking Medicine Technology:Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4
... Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today announced ... of 3.97 million shares of its common stock to institutional ... proceeds of $3.97 million. , The shares were offered ... the Securities and Exchange Commission that was declared effective on ...
... FRANKLIN LAKES, N.J., Oct. 6 BD (Becton, Dickinson and ... conduct a live webcast of its fourth fiscal quarter and ... 4, 2009 at 10:00 a.m. (ET). BD will issue ... , The webcast of the conference call, along with related ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering 2
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... ( http://www.xareltolawsuitcenter.com/ ) that alleges the death ... bleeding caused by the blood thinner, Bernstein Liebhard LLP ... the U.S. District Court for the Southern District ... Xarelto in January 2012, and suffered a subdural hemorrhage ...
(Date:7/22/2014)... a minimally invasive hysterectomy using electric power morcellation, uterine ... the time of the procedure, according to a study ... that this procedure, in which the uterus is fragmented ... undetected malignancies. , Despite the commercial availability of electric ... prevalence of malignancy at the time of electric power ...
(Date:7/22/2014)... D.C. (PRWEB) July 22, 2014 ... “Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
(Date:7/22/2014)... Cancer (LALCA 2014) will be held August 21 ... still the leading cause of death not only in ... the previous conferences in Chile, Mexico, Argentina and Brazil, ... advances in the treatment and prevention of lung cancer ... , With tobacco being the leading cause of morbi-mortality ...
(Date:7/22/2014)... July 22, 2014 The park is ... the Kendalltown Homeowners Association, Inc., made a ... residential community with the purchase of playground equipment from ... located in beautiful Miami Florida, and is a 475-unit ... of the surrounding landscape has created a tropical paradise ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... will focus on scientist collaboration and streamlining the drug discovery process. , , SAN DIEGO, June 18 , ... Meeting in San Diego, Microsoft Corp. ... solutions designed for the life sciences industry, ... * Trial Launch and Protocol Authoring With the 2007 Microsoft, ...
... food and grocery stores , , CHICAGO, June 18 ... of Food Deserts on Public Health in Chicago identified more ... food is hard to come by because of the lack of ... market, community and government actors used the report to take action. ...
... ... Simon will teach stressed New Yorkers how to heal anxiety and experience greater physical health and ... New York City, NY ... Wellbeing , David Simon, M.D., is coming to New York City this June with the launch ...
... introduces proven behavioral health programs from Health Integrated to ... Health Plan members with behavioral health conditions , ... Plan, the nation,s largest public health plan, and Health ... are collaborating to improve outcomes for populations being served ...
... 18 The Sebastian Ferrero Foundation has ... marketing, promotions and publicity. The Gainesville, Florida based firm will begin ... Noche de Gala taking place October 3, 2009. ... an excellent agency with a proven track record of innovation and ...
... Connectyx (Pink Sheets: CTYX) - Connectyx Technologies Holdings Group, ... into an agreement with Sabrielle GPS High Tech to distribute ... Asia market. The initial sales will be targeted to ... allows for the expansion into neighboring countries starting as early ...
Cached Medicine News:Health News:Microsoft to Showcase Clinical Trial Solutions From Discovery to Approvals at Drug Information Association's 2009 Annual Meeting 2Health News:Chicago Making Progress Shrinking Vast 'Food Desert' 2Health News:Chopra Center Co-Founder and Best-Selling Author David Simon, M.D., Will Lead Two Special Events in New York City This June 2Health News:Chopra Center Co-Founder and Best-Selling Author David Simon, M.D., Will Lead Two Special Events in New York City This June 3Health News:L.A. Care Health Plan and Health Integrated Partner to Integrate Medical and Behavioral Support Programs for L.A. Care's Providers 2Health News:L.A. Care Health Plan and Health Integrated Partner to Integrate Medical and Behavioral Support Programs for L.A. Care's Providers 3Health News:Sebastian Ferrero Foundation Selects Gainesville, Florida Based Frankel Media Group as Agency of Record 2Health News:Connectyx Technologies Signs Distributor to Serve the Vast South East Asia Market with its MedFlash Electronic Personal Health Record 2
... Titanium Staples for use with PI™ (Single ... ,The PI™ disposable stapler is designed for ... normal, healthy internal tissues. The instrument places ... row, when using the 30 VASCULAR cartridges) ...
... GIA™ Reloadable Staplers and the SGIA™ ... gynecological, pediatric and thoracic surgical procedures ... anastomosis. , ,The Auto Suture™ ... Knifeless Stapler have application in abdominal, ...
... are anastomotic staplers available in four sizes ... lumen diameter. The staplers permit tissue attachment ... access and ease of use. The instruments ... by adjusting the height of the closed ...
... Sizer Device for use with ... Anastomosis Ring)., ,The Purstring™ ... colorectal and esophageal surgery for ... sutures and is intended for ...
Medicine Products: